EUVIMEDEUVIMED entdecken
Crossref

TOPM (Translational Oncotype Prediction Model): Development and Internal Validation of an Interpretable Clinicopathological Model for Pre-Test Estimation of High Oncotype DX Recurrence Score in Early Hormone Receptor–Positive, HER2-negative Breast Cancer

Orcun Can, Cihan Uras

International Journal of Drug Delivery Technology · 13.08.2026 · 16 (75s)

DOI: 10.25258/ijddt.16.75s.6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 13.08.2026. Verfasst von Orcun Can und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

.

Zitieren

APA

Can, O., & Uras, C. (2026). TOPM (Translational Oncotype Prediction Model): Development and Internal Validation of an Interpretable Clinicopathological Model for Pre-Test Estimation of High Oncotype DX Recurrence Score in Early Hormone Receptor–Positive, HER2-negative Breast Cancer. International Journal of Drug Delivery Technology, 16(75s). https://doi.org/10.25258/ijddt.16.75s.6

Vancouver

Can O, Uras C. TOPM (Translational Oncotype Prediction Model): Development and Internal Validation of an Interpretable Clinicopathological Model for Pre-Test Estimation of High Oncotype DX Recurrence Score in Early Hormone Receptor–Positive, HER2-negative Breast Cancer. International Journal of Drug Delivery Technology. 2026;16(75s). doi:10.25258/ijddt.16.75s.6

BibTeX
@article{Can2026,
  author = {Can, Orcun and Uras, Cihan},
  title = {TOPM (Translational Oncotype Prediction Model): Development and Internal Validation of an Interpretable Clinicopathological Model for Pre-Test Estimation of High Oncotype DX Recurrence Score in Early Hormone Receptor–Positive, HER2-negative Breast Cancer},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {75s},
  doi = {10.25258/ijddt.16.75s.6}
}
Kostenlos starten →